XBIO vs ARTV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 14, 2026

XBIO

33.3
AI Score
VS
ARTV Wins

ARTV

35.2
AI Score

Investment Advisor Scores

XBIO

33score
Recommendation
SELL

ARTV

35score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric XBIO ARTV Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 36.0% -100.0% XBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 33.3/100 35.2/100 ARTV
Profit Margin -70.0% 0.0% ARTV
Beta 1.00 1.00 Tie
AI Recommendation SELL SELL Tie

Relative Price Performance (Last 90 Days)

XBIO 1M: +33.7% · 3M: +22.1% ARTV 1M: +7.9% · 3M: +36.8%

Current Technical Phase

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 74

RSI (14): 73.6 · Price: $3.59

ARTV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (13.9% over 20 days), RSI 51

RSI (14): 50.8 · Price: $10.93

Fundamentals Snapshot

Metric XBIO ARTV
Market Cap
Forward P/E -10.0 -4.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.1% -1.0%
Gross Margin 1.0%
Operating Margin -1.5% 0.0%
EPS -1.16 -3.08
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ARTV is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.